KMT2A and acute myeloid leukemia: 22 miRNAs differentially expressed between t(8;21), t(15;17) and MLL-rearranged AML samples were sufficient to correctly predict 62 out of 71 patient samples belonging to those three groups out of all AML patient samples (Table 2; Figure S1) while nine miRNAs (Table 2) were predictors when preselecting patient samples of these three cytogenetic subtypes.